Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk Patients with SARS-Cov-2 Omicron During BA.2, BA.2.12.1 and BA.5 Subvariants Dominated Era https://www.medrxiv.org/content/10.1101/2022.12.06.22283183
Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk Patients with SARS-Cov-2 Omicron During BA.2, BA.2.12.1 and BA.5 Subvariants Dominated Era https://www.medrxiv.org/content/10.1101/2022.12.06.22283183
@medrxivpreprint #IDMastodon the BEB MA use lacked efficacy in patients with #SarsCoV2 #Omicron subs. Under the light of the current study findings and an expectation of the majority of Omicron sub becoming resistant
https://www.medrxiv.org/content/10.1101/2022.12.06.22283183v1.full.pdf+html